All articles by vemula pravalika
vemula pravalika
FIND and WHO sign new MoU to speed up innovation and access to quality diagnostics
FIND and the World Health Organization (WHO) have signed a new Memorandum of Understanding (MoU) that lays the foundation for accelerating innovation and achieving equitable accesss to quality diagnostics for people globally.
QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis for use on its digital PCR platform QIAcuity and several other enhancements in its GeneGlobe Design and Analysis Hub, a comprehensive research platform that integrates pre-designed assays with a database of more than 10,000 biological entities including genes, miRNAs, and pathways. The new advancements aim to support customers with a wide range of assay customization options, from simple to complex and validated multiplex assays, while further improving the user experience.
Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions
Applied Biosystems™ CytoScan™ Dx and Chromosome Analysis Suite (ChAS) Dx software provide complete solution to support cytogenetic testing
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS) test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer and is expected to enhance decentralized testing capacities once a regulated product is developed with pharmaceutical partners. The project builds on the recently announced master collaboration agreement between the two companies.
QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QIAseq Multimodal DNA/RNA Lib Kit. The new kit enables seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS), as well as downstream target enrichment based on hybrid-capture from a single sample.
MEDICA INNOVATION FORUM for the healthcare innovations of the future
Keynote speeches, tech talks, panel talks and pitch sessions on all the leading digitalisation trends
New Frontier acquires oncology medical platform HKIOC
The deal will see HKIOC partnering with New Frontier’s subsidiary HEAL Oncology to create a formidable entity in oncology sector.
WHO releases a strategic framework for enhancing prevention and control of mpox
Mpox continues to affect people around the world. A new framework released today by WHO will guide health authorities, communities and other stakeholders in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the virus from animals to humans.
New 5-year plan to combat antimicrobial resistance
The government has announced its new national action plan on antimicrobial resistance to protect people and animals from the risk of drug-resistant infections.
QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use.